Skip to main content
. Author manuscript; available in PMC: 2017 Jan 26.
Published in final edited form as: Acta Otolaryngol. 2010 Feb;130(2):215–222. doi: 10.3109/00016480903019251

Figure 4.

Figure 4

Activity of different promoters in inner ear tissue was assessed by using luciferase-expressing vector in macular organ cultures and measuring the average luciferase activity per μg of extracted protein over time. Results are expressed in a logarithmic scale due to significant differences in expression when comparing promoter types. Use of the human CMV promoter resulted in a steady level of luciferase production (Ad.hCMV.L.). The ubiquitin promoter demonstrated a slow decline of luciferase production over the 2 week study period (AdUb.L.). Expression of luciferase driven by the hybrid CMV enhancer/chicken β-actin promoter resulted in a steady increase in luciferase production (AdcBA.L.). Use of a supporting cell-specific promoter (GFAP) resulted in very low levels of luciferase production (Ad.GFAP.L). At 7 and 14 days post delivery, luciferase levels were significantly different for all groups (p < 0.01). n = 10 for each condition.